We are developing a diverse pipeline of product candidates for both rare and large market diseases, including patient populations that other genetic medicines are unable to address. Our initial product candidates are focused in the following therapeutic areas: ophthalmology, cardiology and pulmonology. Each of our product candidates leverages a targeted and evolved vector we invented through our Therapeutic Vector Evolution platform.
|
VECTOR
Delivery
|
PRODUCT
CANDIDATE
|
INDICATION
|
TVP
SELECTION
|
LEAD
OPTIM.
|
IND-
ENABLING
|
PHASE 1/2
|
PHASE 3
|
PRODUCT
RIGHTS
|
|---|---|---|---|---|---|---|---|---|
|
R100
Intravitreal
|
OPHTHALMOLOGY | |||||||
| 4D-150 | Wet AMD | |||||||
| DME | ||||||||
| 4D-125 | XLRP | |||||||
| 4D-110 | CHM | |||||||
|
C102
IV
|
CARDIOLOGY | |||||||
| 4D-310 | Fabry Disease |
|||||||
|
A101
Aerosol
|
PULMONOLOGY | |||||||
| 4D-710 | Cystic Fibrosis | |||||||